The Role of 18F-FDG PET/CT on Staging and Prognosis in Patients with Small Cell Lung Cancer

Abstract

• Identifying variables that predict the prognosis of patients with SCLC is important. • 18F-FDG PET/CT influences staging of patients with SCLC. • Metabolic parameters could be used as predictors for PFS and OS.

Prognostic value of metabolic tumour volume and total lesion glycolysis measured by 18F‐fluorodeoxyglucose positron emission tomography/computed tomography in small cell lung cancer: A systematic review and meta‐analysis

“…We used the univariate HR and 95% CI from each eligible article, except for the study by Zer et al . where only adjusted HRs from multivariate analyses were obtainable . Two studies by the same group (Oh et al .)…”

“…This included primary tumour, lymph nodes, and distant metastases. Three studies measured MTV and TLG only in the thorax (MTV TRX and TLG TRX ) . The remaining study evaluated both MTV WB and MTV TRX .…”

18F-Fludeoxyglucose PET/CT in SCLC: Analysis of the CONVERT Randomized Controlled Trial

“…These studies showed that 18 F-FDG PET or 18 F-FDG PET/CT upstages 0% to 47% of limited-stage patients, but the results are inconsistent and many studies had significant bias. 16,18,19,29 Additional references are listed in Supplement 2. Furthermore and unlike in NSCLC studies, the rapid SCLC doubling time, coupled with the lack of need for precise anatomic histological staging to inform treatment decisions, has nearly always precluded histological validation of 18 F-FDG PET or 18 F-FDG PET/ CT findings.…”

“…15 Small retrospective and nonrandomized prospective studies have shown that 18 F-FDG PET or 18 F-FDG PET/CT improves SCLC staging accuracy, with pretreatment metabolic and volumetric 18 F-FDG PET parameters providing additional prognostic information. [16][17][18][19] Oncology practice guidelines (e.g., the National Comprehensive Cancer Network guidelines) now recommend or suggest using 18 F-FDG PET/CT when staging patients with SCLC. [20][21][22][23] However, landmark phase 3 trials that established chemoradiotherapy as standard treatment in limited-staged SCLC were performed before the 18 F-FDG PET/CT era.…”

Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging in Diagnosis and Staging of Lung Cancer

“…Yaygın hastalığın belirlenmesinde FDG PET/BT görüntülemenin tanısal rolünü araştıran çalışmaların incelendiği bir meta-analiz çalışmasında ortalama duyarlılık ve özgüllük değerleri sırarıyla %97 ve %98 olarak bulunmuştur (Tablo 2) (36). Evrelemede FDG PET/BT görüntülemenin kullanılması KHAK evresinde ve tedavi planında %11-%37 oranında değişikliğe neden olmaktadır (37,38,39). Akciğer kanserinde genel olarak gözlenen SUV maks ve metabolik tümör volümü (MTV) değerleri ile sağkalım arasındaki ilişkiler KHAK için de geçerlidir (39,40,41).…”